Perspective Therapeutics, Inc. (CATX) stock
CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.75−0.03 (-3.85%)
Close on Nov 20, 2026Market cap $86.05MP/E –Yield –
Perspective Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Perspective Therapeutics's profit margin for the twelve months ending Jun 30, 2022 was -67.4%. For fiscal 2022 it was -67.4%, against -33.7% the year before. The highest annual figure on record is -33.7% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | -67.4% | −33.7 |
| FY2021 | Jun 30, 2021 | -33.7% | +1.9 |
| FY2020 | Jun 30, 2020 | -35.6% | +34.7 |
| FY2019 | Jun 30, 2019 | -70.3% | +42.8 |
| FY2018 | Jun 30, 2018 | -113.1% | +16.3 |
| FY2017 | Jun 30, 2017 | -129.4% | −30.6 |
| FY2016 | Jun 30, 2016 | -98.8% | −18.9 |
| FY2015 | Jun 30, 2015 | -79.9% | +61.3 |
| FY2014 | Jun 30, 2014 | -141.2% | −56.0 |
| FY2013 | Jun 30, 2013 | -85.2% | −16.4 |
| FY2012 | Jun 30, 2012 | -68.8% | −14.5 |
| FY2011 | Jun 30, 2011 | -54.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -83.0% | −43.8 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -46.3% | −17.6 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -57.0% | −20.2 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -87.5% | −57.6 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -39.2% | +13.0 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -28.7% | −9.7 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -36.8% | +3.9 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -29.9% | +5.3 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -52.1% | +4.8 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -18.9% | +39.7 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -40.7% | +33.6 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -35.2% | +61.3 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -56.9% | +89.3 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -58.6% | +26.1 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -74.3% | +21.0 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -96.5% | +31.1 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -146.2% | −10.8 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -84.7% | +21.4 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -95.2% | +45.8 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -127.7% | +10.9 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -135.3% | −29.5 |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -106.1% | −6.3 |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -141.1% | −30.7 |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -138.6% | −57.8 |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -105.8% | −28.6 |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -99.7% | −17.4 |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -110.3% | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -80.8% | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -77.2% | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -82.3% | – |
See a number that looks wrong?